LEADER 01549nam  2200457   450 
001 9910478881603321
010   $a0-309-45795-5
035   $a(CKB)4340000000252744
035   $a(MiAaPQ)EBC5295066
035   $a(EXLCZ)994340000000252744
100   $a20180310h20182018  uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 04$aThe drug development paradigm in oncology $eproceedings of a workshop /$fAmanda Wagner Gee [and three others], rapporteurs
210  1$aWashington, District of Columbia :$cThe National Academies Press,$d2018.
210  4$dİ2018
215   $a1 online resource (122 pages) $cillustrations (some color)
311   $a0-309-45794-7 
320   $aIncludes bibliographical references at the end of each chapters.
606   $aClinical trials$zUnited States$vCongresses
606   $aDrug development$zUnited States$vCongresses
606   $aDevelopmental pharmacology$zUnited States
608   $aElectronic books.
615  0$aClinical trials
615  0$aDrug development
615  0$aDevelopmental pharmacology
676   $a610.724
702   $aGee$b Amanda Wagner
712 02$aNational Cancer Policy Forum.
712 02$aBoard on Health Care Services.
712 02$aHealth and Medicine Division.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910478881603321
996   $aThe drug development paradigm in oncology$92271269
997   $aUNINA